First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema
02 août 2023 08h00 HE
|
Oculis Operations Sarl
LEOPARD trial initiation follows recent positive data from OCS-01 eye drops from the Stage 1 Phase 3 DIAMOND trial in patients with Diabetic Macular Edema (DME)Cystoid Macular Edema (CME) can result...
Oculis Announces to Present at Upcoming August Investor Conferences
26 juil. 2023 08h00 HE
|
Oculis SA
ZUG, Switzerland, and BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis to Present at OIS Retina Innovation Summit
19 juil. 2023 08h00 HE
|
Oculis SA
ZUG, Switzerland, and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
26 juin 2023 08h00 HE
|
Oculis SA
R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00 PM EDT at the Lotte New York Palace Hotel and onlineCo-principal investigators, Dr. David S. Boyer and Dr....
Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
13 juin 2023 16h01 HE
|
Oculis SA
ZUG, Switzerland and BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics
12 juin 2023 08h00 HE
|
Oculis SA
The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders Professors Einar Stefánsson, and Thorsteinn Loftsson. OPTIREACH is behind Oculis’...
Oculis to Participate in Jefferies Healthcare Conference
01 juin 2023 08h00 HE
|
Oculis SA
ZUG, Switzerland and BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares
31 mai 2023 23h59 HE
|
Oculis SA
ZUG, Switzerland and BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis Announces Launch of Proposed Public Offering of Ordinary Shares
30 mai 2023 07h06 HE
|
Oculis SA
ZUG, Switzerland and BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis to Participate and Present at Upcoming EuDES Meeting
24 mai 2023 08h00 HE
|
Oculis SA
ZUG, Switzerland and BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...